CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

References

• AllegriMMontellaSSaliciFMechanisms of low back pain: a guide for diagnosis and therapyF1000Res201651530
   Google Scholar
• WongAYKarppinenJSamartzisDLow back pain in older adults: risk factors, management options and future directionsScoliosis Spinal Disord2017121428435906
   PubMedGoogle Scholar
• PetitARoche-LeboucherGBontouxLEffectiveness of three treatment strategies on occupational limitations and quality of life for patients with non-specific chronic low back pain: is a multidisciplinary approach the key feature to success: study protocol for a randomized controlled trialBMC Musculoskelet Disord2014151513124739659
   PubMed Web of Science ®Google Scholar
• CampbellPFosterNEThomasEDunnKMPrognostic indicators of low back pain in primary care: five-year prospective studyJ Pain201314887388323791041
   PubMed Web of Science ®Google Scholar
• FreidinMBKeserTGudeljIThe association between low back pain and composition of IgG glycomeSci Rep201662681527229623
   PubMed Web of Science ®Google Scholar
• LippiGDagostinoCBuonocoreRThe serum concentrations of leptin and MCP-1 independently predict low back pain durationClin Chem Lab Med20175591368137428076310
   PubMed Web of Science ®Google Scholar
• AllegriMde GregoriMMinellaCE‘Omics’ biomarkers associated with chronic low back pain: protocol of a retrospective longitudinal studyBMJ Open2016610e012070
   Web of Science ®Google Scholar
• SuriPBoykoEJSmithNLModifiable risk factors for chronic back pain: insights using the co-twin control designSpine J201717141427794503
   PubMed Web of Science ®Google Scholar
• MalkinIWilliamsFMLachanceGSpectorTMacgregorAJLivshitsGLow back and common widespread pain share common genetic determinantsAnn Hum Genet201478535736624962672
   PubMed Web of Science ®Google Scholar
• WilliamsFMBansalATvan MeursJBNovel genetic variants associated with lumbar disc degeneration in northern Europeans: a meta-analysis of 4600 subjectsAnn Rheum Dis20137271141114822993228
   PubMed Web of Science ®Google Scholar
• KayeADJonesMRKayeAMPrescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2)Pain Physician2017202SS111S13328226334
   PubMed Web of Science ®Google Scholar
• ReimerJWrightNSomainiLThe impact of misuse and diversion of opioid substitution treatment medicines: evidence review and expert consensusEur Addict Res20162229910626426530
   PubMed Web of Science ®Google Scholar
• DavisMPPharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back painExpert Opin Drug Metab Toxicol201612782383127253690
   PubMed Web of Science ®Google Scholar
• MuscoliCDagostinoCIlariSPosttranslational nitration of tyrosine residues modulates glutamate transmission and contributes to N-methyl-d-aspartate-mediated thermal hyperalgesiaMediators Inflamm20132013112
   Web of Science ®Google Scholar
• TingSSchugSThe pharmacogenomics of pain management: prospects for personalized medicineJ Pain Res201699495626929662
   PubMed Web of Science ®Google Scholar
• LeppertWCYP2D6 in the metabolism of opioids for mild to moderate painPharmacology2011875–627428521494059
   PubMed Web of Science ®Google Scholar
• de GregoriMAllegriMde GregoriSHow and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatmentsCurr Drug Metab201011327628221171195
   PubMed Web of Science ®Google Scholar
• ChoiSWLamDMHWongSSCShiuHHCWangAXMCheungCWEffects of single nucleotide polymorphisms on surgical and postsurgical opioid requirements: a systematic review and meta-analysisClin J Pain201733121113027153359
   PubMed Web of Science ®Google Scholar
• CavallariLHJeongHBressARole of cytochrome P450 genotype in the steps toward personalized drug therapyPharmgenomics Pers Med2011412313623226058
   PubMedGoogle Scholar
• MadadiPRossCJHaydenMRPharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control studyClin Pharmacol Ther2009851313518719619
   PubMed Web of Science ®Google Scholar
• ChidambaranVSadhasivamSMahmoudMCodeine and opioid metabolism: implications and alternatives for pediatric pain managementCurr Opin Anaesthesiol201730334935628323671
   PubMed Web of Science ®Google Scholar
• SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte – an update of guidelinesClin Pharmacol Ther201189566267321412232
   PubMed Web of Science ®Google Scholar
• DepriestAZPuetBLHoltACRobertsAConeEJMetabolism and disposition of prescription opioids: a reviewForensic Sci Rev201527211514526227254
   PubMedGoogle Scholar
• FloresCMMogilJSThe pharmacogenetics of analgesia: toward a genetically-based approach to pain managementPharmacogenomics20012317719411535108
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMSimSCGomezARodriguez-AntonaCInfluence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacol Ther2007116349652618001838
   PubMed Web of Science ®Google Scholar
• LammersLAAchterberghRvan SchaikRHNRomijnJAMathôtRAAEffect of short-term fasting on systemic cytochrome P450-mediated drug metabolism in healthy subjects: a randomized, controlled, crossover study using a cocktail approachClin Pharmacokinet201756101231124428229374
   PubMed Web of Science ®Google Scholar
• FijalBAGuoYLiSGCYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trialJ Clin Pharmacol201555101167117425919121
   PubMed Web of Science ®Google Scholar
• RebsamenMCDesmeulesJDaaliYThe AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype predictionPharmacogenomics J200991344118591960
   PubMed Web of Science ®Google Scholar
• St SauverJLOlsonJERogerVLCYP2D6 phenotypes are associated with adverse outcomes related to opioid medicationsPharmgenomics Pers Med20171021722728769582
   PubMed Web of Science ®Google Scholar
• MorlockRBraunsteinGDPharmacoeconomics of genotyping-based treatment decisions in patients with chronic painPain Rep201725e61529392230
   PubMedGoogle Scholar
• NgGQSklarGEChngHTAn evaluation of the completeness of drug–drug interaction-related information in package insertsEur J Clin Pharmacol201773216517427796467
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• BaharMASetiawanDHakEWilffertBPharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6Pharmacogenomics201718770173928480783
   PubMed Web of Science ®Google Scholar
• DagostinoCde GregoriMGiegerCValidation of standard operating procedures in a multicenter retrospective study to identify -omics biomarkers for chronic low back painPLoS One2017125e017637228459826
   PubMed Web of Science ®Google Scholar
• KimuraSUmenoMSkodaRCMeyerUAGonzalezFJThe human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogeneAm J Hum Genet19894568899042574001
   PubMed Web of Science ®Google Scholar
• MarezDLegrandMSabbaghNPolymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics1997731932029241659
   PubMedGoogle Scholar
• SachseCBrockmöllerJBauerSRootsICytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequencesAm J Hum Genet19976022842959012401
   PubMed Web of Science ®Google Scholar
• JohanssonILundqvistEBertilssonLDahlMLSjöqvistFIngelman-SundbergMInherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquineProc Natl Acad Sci U S A1993902411825118297903454
   PubMed Web of Science ®Google Scholar
• PanseratSMuraCGérardNDNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisersHum Genet19949444014067927337
   PubMed Web of Science ®Google Scholar
• RaimundoSFischerJEichelbaumMGrieseEUSchwabMZangerUMElucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6Pharmacoge-netics2000107577581
   PubMed Web of Science ®Google Scholar
• KagimotoMHeimMKagimotoKZeuginTMeyerUAMultiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genesJ Biol Chem19902652817209172142211621
   PubMed Web of Science ®Google Scholar
• GoughACMilesJSSpurrNKIdentification of the primary gene defect at the cytochrome P450 CYP2D locusNature199034762957737761978251
   PubMed Web of Science ®Google Scholar
• HaniokaNKimuraSMeyerUAGonzalezFJThe human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition siteAm J Hum Genet19904769951001
   Web of Science ®Google Scholar
• GaedigkABlumMGaedigkREichelbaumMMeyerUADeletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphismAm J Hum Genet19914859439501673290
   PubMed Web of Science ®Google Scholar
• SteenVMMolvenAAarskogNKGulbrandsenAKHomologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 geneHum Mol Genet1995412225122578634695
   PubMed Web of Science ®Google Scholar
• EvertBGrieseEUEichelbaumMCloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codonPharmacogenetics1994452712747894499
   PubMedGoogle Scholar
• SaxenaRShawGLRellingMVIdentification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeHum Mol Genet1994369239267951238
   PubMed Web of Science ®Google Scholar
• DalyAKLeathartJBLondonSJIdleJRAn inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitutionHum Genet19959533373417868129
   PubMed Web of Science ®Google Scholar
• EvertBGrieseEUEichelbaumMA missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteineNaunyn Schmiedebergs Arch Pharmacol199435044344397845481
   PubMed Web of Science ®Google Scholar
• BrolyFMarezDLo GuidiceJMA nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiencyHum Genet19959656016038530011
   PubMed Web of Science ®Google Scholar
• TyndaleRAoyamaTBrolyFIdentification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics19911126321844820
   PubMedGoogle Scholar
• BrolyFMeyerUADebrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 genePharmacogenetics1993331231308101460
   PubMedGoogle Scholar
• SakuyamaKSasakiTUjiieSFunctional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)Drug Metab Dispos200836122460246718784265
   PubMed Web of Science ®Google Scholar
• MarezDSabbaghNLegrandMLo-GuidiceJMBoonePBrolyFA novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotypePharmacogenetics1995553053118563771
   PubMedGoogle Scholar
• MasimirembwaCPerssonIBertilssonLHaslerJIngelman-SundbergMA novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activityBr J Clin Pharmacol19964267137198971426
   PubMed Web of Science ®Google Scholar
• OscarsonMHidestrandMJohanssonIIngelman-SundbergMA combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme functionMol Pharmacol1997526101040
   Web of Science ®Google Scholar
• WennerholmAJohanssonIHidestrandMBertilssonLGustafssonLLIngelman-SundbergMCharacterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activityPharmacogenetics200111541742711470994
   PubMedGoogle Scholar
• WennerholmADandaraCSayiJThe African-specific CYP2D617 allele encodes an enzyme with changed substrate specificityClin Pharmacol Ther2002711778811823760
   PubMed Web of Science ®Google Scholar
• GaedigkARyderDLBradfordLDLeederJSCYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphismClin Chem2003496 Pt 11008101112766015
   PubMed Web of Science ®Google Scholar
• RaimundoSToscanoCKleinKA novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjectsClin Pharmacol Ther200476212813815289790
   PubMed Web of Science ®Google Scholar
• MeyerUAPharmacogenetics and adverse drug reactionsLancet200035692421667167111089838
   PubMed Web of Science ®Google Scholar
• RogersJFNafzigerANBertinoJSPharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugsAm J Med2002113974675012517365
   PubMed Web of Science ®Google Scholar
• ScordoMGCaputiAPD’ArrigoCFavaGSpinaEAllele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian populationPharmacol Res200450219520015177309
   PubMed Web of Science ®Google Scholar
• HaufroidVHantsonPCYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressantsClin Toxicol2015536501510
   PubMed Web of Science ®Google Scholar
• DudbridgeFPedigree disequilibrium tests for multilocus haplotypesGenet Epidemiol200325211512112916020
   PubMed Web of Science ®Google Scholar
• FengXQZhuLLZhouQOpioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk managementJ Pain Res2017101225123928579821
   PubMed Web of Science ®Google Scholar
• ForoutanBPersonalized medicine: a review with regard to biomarkersJ Bioequiv Availab20150706244256
   Google Scholar
• ZhangXDPrecision medicine, personalized medicine, omics and big data: concepts and relationshipsJ Pharmacogenomics Pharmacoproteomics20150622
   Google Scholar
• SchleyerTKingZMiledZBA novel conceptual architecture for person-centered health recordsAMIA Annu Symp Proc201620161090109928269906
   PubMedGoogle Scholar
• FinnerupNBAttalNHaroutounianSPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysisLancet Neurol201514216217325575710
   PubMed Web of Science ®Google Scholar
• ShepherdGMohornPYacoubKMayDWAdverse drug reaction deaths reported in United States vital statistics, 1999–2006Ann Pharmacother201246216917522253191
   PubMed Web of Science ®Google Scholar
• MaticMde WildtSNTibboelDvan SchaikRHNAnalgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practiceClin Chem20176371204121328637770
   PubMed Web of Science ®Google Scholar
• KoTMWongCSWuJYChenYTPharmacogenomics for personalized pain medicineActa Anaesthesiol Taiwan2016541243026976339
   PubMedGoogle Scholar
• CrewsKRGaedigkADunnenbergerHMClinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 updateClin Pharmacol Ther201495437638224458010
   PubMed Web of Science ®Google Scholar
• BernardSNevilleKANguyenATFlockhartDAInterethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implicationsOncologist200611212613516476833
   PubMed Web of Science ®Google Scholar
• WebsterLRBelferIPharmacogenetics and personalized medicine in pain managementClin Lab Med201636349350627514464
   PubMed Web of Science ®Google Scholar
• GregoriMGregoriSRanzaniGNAllegriMGovoniSRegazziMIndividualizing pain therapy with opioids: the rational approach based on pharmacogenetics and pharmacokineticsEur J Pain Suppl20104S4245250
   Google Scholar
• SomogyiAACollerJKBarrattDTPharmacogenetics of opioid responseClin Pharmacol Ther201597212512725670515
   PubMed Web of Science ®Google Scholar
• SolhaugVMoldenEIndividual variability in clinical effect and tolerability of opioid analgesics – importance of drug interactions and pharmacogeneticsScand J Pain20171719320029054049
   PubMed Web of Science ®Google Scholar
• LloydRAHothamEHallCWilliamsMSuppiahVPharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: a focus on morphine, oxycodone, tramadol, and fentanylPain Med201718122369238728339912
   PubMed Web of Science ®Google Scholar
• LinaresOADalyDLinaresADStefanovskiDBostonRCPersonalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectivenessPain Med201415579180624517173
   PubMed Web of Science ®Google Scholar